• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Tolvaptan, a vasopressin receptor 2 antagonist, shows promise in polycystic kidney disease (TEMPO trial)

bys25qthea
December 26, 2012
in Chronic Disease, Nephrology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

[tabs tab1=”2MM Rundown” tab2= “Full 2MM Report” tab3=”About the Authors”]

[tab]

Image: PD/CDC. Cystic kidneys, gross pathology. 

1. Tolvaptan can slow progression of autosomal dominant polycystic kidney disease both in terms of kidney volume and kidney function. 

2. Side effects of tolvaptan are mainly related to water loss due to its function as a V2 receptor antagonist. 

Tolvaptan appears to offer a promising option for the treatment of ADPKD. However, the authors note that the aquaretic side effects of the drug (e.g. thirst, polyuria) pose a barrier to patient tolerance of and adherence to the medication.

[/tab]

RELATED REPORTS

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

Plant-based diets may be associated with lower risk of aggressive prostate cancer

#VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab

[tab]

Image: PD/CDC. Cystic kidneys, gross pathology. 

1. Tolvaptan can slow progression of autosomal dominant polycystic kidney disease both in terms of kidney volume and kidney function. 

2. Side effects of tolvaptan are mainly related to water loss due to its function as a V2 receptor antagonist. 

Primer: Autosomal dominant Polycystic Kidney Disease (ADPKD) causes a progressive decline in kidney function associated with extensive formation of renal cysts. The vast majority of mutations are in the PKD1 locus on chromosome 16. Most of the remainder cases are due to mutations in the PKD2 locus on chromosome 4. The mechanism of cyst formation is not completely known, but appears to require loss of the wild-type copy of PKD1 in heterozygous cells (similar to the two-hit hypothesis of carcinogenesis).

Vasopressin (aka anti-diuretic hormone or ADH) mainly regulates water reabsorption in the collecting ducts. It mediates this through the vasopressin V2 receptor, a G-protein coupled receptor that works through adenylyl cyclase to increase cAMP levels. Through other receptors, vasopressin can also cause peripheral vasoconstriction and have effects within the brain.

Previous studies have shown that reduced vasopressin signaling in the collecting duct can slow progression of ADPKD. The mechanism is believed to involve reduced cAMP levels in the kidney. The TEMPO trial is a phase 3 study testing the efficacy and safety of using the V2-receptor antagonist tolvaptan in patients with ADPKD. Tolvaptan is already in use for treatment of conditions like hyponatremia.

Background reading:

  1. Up-to-date page on genetics of ADPKD and mechanisms of cyst growth
  2. Mouse model of ADPKD benefits from V2-receptor antagonist

This [phase 3 randomized controlled] study: 961 ADPKD patients were assigned to tolvaptan, while 484 were assigned to placebo as controls. The primary end point of the study was change in total kidney volume over a 3-year period (treatment goals being to minimize volume increase). In the tolvaptan group, total kidney volume increased by 2.8% per year versus 5.5% per year in the placebo group (P<0.001).

Using the reciprocal slope of mean serum creatinine levels as a proxy for rate of decline in kidney function, the tolvaptan group demonstrated significantly less functional decline vs. placebo. In addition, fewer ADPKD-related events per 100 persons years were observed in the tolvaptan vs. placebo group (44 vs. 50; P = 0.01) In short, the tolvaptan group had a slower decline in kidney function than the placebo group and this was reflected in a lower rate of disease-related events.

In sum: Tolvaptan appears to offer a promising option for the treatment of ADPKD. However, the authors note that the aquaretic side effects of the drug (e.g. thirst, polyuria) pose a barrier to patient tolerance of and adherence to the medication.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

By [TJ] and [MS]

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

[/tab]

[tab]

Tomi Jun: Tomi is a member of the class of 2015 in the Health Sciences and Technology program at HMS. He enjoys road biking and molecular biology.

 

 

 

 

[/tab]

[/tabs]

Previous Post

Hospitals are not exempt from gun violence

Next Post

The ONTARGET trial: Telmisartan is non-inferior to ramipril in improving cardiovascular outcomes in high-risk populations [Classics Series]

RelatedReports

Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

January 27, 2023
Vegetarian diet may lower incidence of colorectal cancer
Lifestyle

Plant-based diets may be associated with lower risk of aggressive prostate cancer

January 27, 2023
#VisualAbstract: Telehealth treatment is effective in managing behavior problems in children with developmental delay
StudyGraphics

#VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab

January 27, 2023
2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

January 26, 2023
Next Post
Classics Series, Landmark Trials in Medicine

The ONTARGET trial: Telmisartan is non-inferior to ramipril in improving cardiovascular outcomes in high-risk populations [Classics Series]

[Researcher Comment] Replace peripheral intravenous catheters as clinically-indicated

Discrepency in sepsis care identified between the United States and Europe

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options